Shahid Aqsa, Chambers Stephen, Scott-Thomas Amy, Bhatia Madhav
Department of Pathology and Biomedical Science, University of Otago, Christchurch 8140, New Zealand.
Int J Mol Sci. 2024 Dec 14;25(24):13415. doi: 10.3390/ijms252413415.
Sepsis is a life-threatening complication caused by an uncontrolled immune response to infection that can lead to multi-organ dysfunction, including liver injury. Recent research has shown the critical role of gut microbiota in sepsis pathogenesis, with the gut-liver axis playing a crucial role in disease progression. Mechanisms such as the disruption of the gut barrier and liver injury pathways mediated by cytokines, chemokines, adhesion molecules, hydrogen sulfide (HS). and substance P (SP) have been the focus of recent studies. Some potential biomarkers and gut microbiota-targeted therapies have shown promise as emerging tools for predicting and managing sepsis. This review describes the role of the gut-liver axis in sepsis and the potential of microbiota-targeted therapies and biomarker-driven interventions to improve sepsis outcomes.
脓毒症是一种由对感染的不受控制的免疫反应引起的危及生命的并发症,可导致多器官功能障碍,包括肝损伤。最近的研究表明肠道微生物群在脓毒症发病机制中起关键作用,肠-肝轴在疾病进展中起至关重要的作用。诸如肠道屏障破坏以及由细胞因子、趋化因子、黏附分子、硫化氢(HS)和P物质(SP)介导的肝损伤途径等机制一直是最近研究的重点。一些潜在的生物标志物和针对肠道微生物群的疗法已显示出作为预测和管理脓毒症的新兴工具的前景。本综述描述了肠-肝轴在脓毒症中的作用以及针对微生物群的疗法和生物标志物驱动的干预措施改善脓毒症结局的潜力。